Edition:
United States

ChemoCentryx Inc (CCXI.OQ)

CCXI.OQ on NASDAQ Stock Exchange Global Select Market

6.33USD
23 Feb 2017
Change (% chg)

$-0.22 (-3.36%)
Prev Close
$6.55
Open
$6.55
Day's High
$6.58
Day's Low
$6.25
Volume
59,806
Avg. Vol
73,579
52-wk High
$9.09
52-wk Low
$1.93

CCXI.OQ

Chart for CCXI.OQ

About

ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $302.61
Shares Outstanding(Mil.): 47.81
Dividend: --
Yield (%): --

Financials

  CCXI.OQ Industry Sector
P/E (TTM): -- 28.81 29.68
EPS (TTM): -0.97 -- --
ROI: -46.37 13.56 13.06
ROE: -64.59 14.44 14.19

BRIEF-Vifor Pharma, ChemoCentryx announce expansion of Avacopan agreement

* Vifor Pharma and ChemoCentryx announce expansion of avacopan agreement for rare renal diseases

Feb 14 2017

BRIEF-Chemocentryx reports Q3 loss per share $0.15

* Chemocentryx reports third quarter 2016 financial results and provides corporate update

Nov 07 2016

BRIEF-Chemocentryx reports presentation of positive data from ongoing pilot phase II trial of CCX168

* Chemocentryx announces presentation of positive data from ongoing pilot phase II trial of CCX168 (avacopan) in atypical hemolytic uremic syndrome (AHUS) at ASN kidney week 2016

Oct 17 2016

BRIEF-ChemoCentryx reports initial results from ongoing phase IB clinical trial of CCX872

* Reports initial results from ongoing phase IB clinical trial of CCX872 in patients with advanced pancreatic cancer

Sep 01 2016

More From Around the Web

Competitors

Earnings vs. Estimates